Home EryDel

EryDel

acquired
-
Rare Disease Drug Developer

Basic Information

EryDel has assembled a team of globally-minded, inspired leaders with extensive experience in the development and commercialization of rare disease drugs, highly committed to providing innovative therapies for patients suffering from rare diseases.
Erydel S.P.A.
Italy
15~50 people
February 01, 2007
--